Literature DB >> 30152256

Meta-analysis of duration of dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention.

Safi U Khan1, Irbaz Bin Riaz2, Hammad Rahman3, Ahmed N Lone1, Munis Raza4, Muhammad Shahzeb Khan5, Anum Riaz6, Edo Kaluski3.   

Abstract

Entities:  

Year:  2018        PMID： 30152256      PMCID： PMC6389365          DOI： 10.1177/2047487318795245

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN： 2047-4873            Impact factor:   7.804


× No keyword cloud information.
  11 in total

Review 1.  Coronary artery disease: Risk stratification and patient selection for more aggressive secondary prevention.

Authors:  François Schiele; Fiona Ecarnot; Romain Chopard
Journal:  Eur J Prev Cardiol       Date:  2017-06       Impact factor: 7.804

Review 2.  Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease.

Authors:  Maddalena Lettino; Sergio Leonardi; Elia De Maria; Sigrun Halvorsen
Journal:  Eur J Prev Cardiol       Date:  2017-06       Impact factor: 7.804

3.  Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.

Authors:  Fausto Feres; Ricardo A Costa; Alexandre Abizaid; Martin B Leon; J Antônio Marin-Neto; Roberto V Botelho; Spencer B King; Manuela Negoita; Minglei Liu; J Eduardo T de Paula; José A Mangione; George X Meireles; Hélio J Castello; Eduardo L Nicolela; Marco A Perin; Fernando S Devito; André Labrunie; Décio Salvadori; Marcos Gusmão; Rodolfo Staico; J Ribamar Costa; Juliana P de Castro; Andrea S Abizaid; Deepak L Bhatt
Journal:  JAMA       Date:  2013-12-18       Impact factor: 56.272

4.  Cardiac rehabilitation programme as a non-pharmacological platelet inhibitory tool in acute coronary syndrome survivors.

Authors:  Emese Tóth-Zsámboki; Zsófia Horváth; László Hajtman; Sarolta Leé; Éva Pállinger; Eszter Kuklis; Ádám Tahy; György Fekete; László Kohut; Róbert G Kiss
Journal:  Eur J Prev Cardiol       Date:  2017-04-25       Impact factor: 7.804

5.  A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation).

Authors:  Byeong-Keuk Kim; Myeong-Ki Hong; Dong-Ho Shin; Chung-Mo Nam; Jung-Sun Kim; Young-Guk Ko; Donghoon Choi; Tae-Soo Kang; Byoung-Eun Park; Woong-Chol Kang; Seung-Hwan Lee; Jung-Han Yoon; Bum-Kee Hong; Hyuck-Moon Kwon; Yangsoo Jang
Journal:  J Am Coll Cardiol       Date:  2012-09-19       Impact factor: 24.094

6.  Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.

Authors:  Marco Valgimigli; Gianluca Campo; Monia Monti; Pascal Vranckx; Gianfranco Percoco; Carlo Tumscitz; Fausto Castriota; Federico Colombo; Matteo Tebaldi; Giuseppe Fucà; Moh'd Kubbajeh; Elisa Cangiano; Monica Minarelli; Antonella Scalone; Caterina Cavazza; Alice Frangione; Marco Borghesi; Jlenia Marchesini; Giovanni Parrinello; Roberto Ferrari
Journal:  Circulation       Date:  2012-03-21       Impact factor: 29.690

7.  Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent: Randomized Substudy of the I-LOVE-IT 2 Trial.

Authors:  Yaling Han; Bo Xu; Kai Xu; Changdong Guan; Quanmin Jing; Qiangsun Zheng; Xueqi Li; Xianxian Zhao; Haichang Wang; Xuezhong Zhao; Xiaoyan Li; Pengfei Yu; Hongyun Zang; Zhifang Wang; Xuebin Cao; Jun Zhang; Wenyue Pang; Jing Li; Yuejin Yang; George D Dangas
Journal:  Circ Cardiovasc Interv       Date:  2016-02       Impact factor: 6.546

8.  Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.

Authors:  Hyeon-Cheol Gwon; Joo-Yong Hahn; Kyung Woo Park; Young Bin Song; In-Ho Chae; Do-Sun Lim; Kyoo-Rok Han; Jin-Ho Choi; Seung-Hyuk Choi; Hyun-Jae Kang; Bon-Kwon Koo; Taehoon Ahn; Jung-Han Yoon; Myung-Ho Jeong; Taek-Jong Hong; Woo-Young Chung; Young-Jin Choi; Seung-Ho Hur; Hyuck-Moon Kwon; Dong-Woon Jeon; Byung-Ok Kim; Si-Hoon Park; Nam-Ho Lee; Hui-Kyung Jeon; Yangsoo Jang; Hyo-Soo Kim
Journal:  Circulation       Date:  2011-12-16       Impact factor: 29.690

9.  ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting.

Authors:  Stefanie Schulz-Schüpke; Robert A Byrne; Jurrien M Ten Berg; Franz-Josef Neumann; Yaling Han; Tom Adriaenssens; Ralph Tölg; Melchior Seyfarth; Michael Maeng; Bernhard Zrenner; Claudius Jacobshagen; Harald Mudra; Eberhard von Hodenberg; Jochen Wöhrle; Dominick J Angiolillo; Barbara von Merzljak; Nonglag Rifatov; Sebastian Kufner; Tanja Morath; Antonia Feuchtenberger; Tareq Ibrahim; Paul W A Janssen; Christian Valina; Yi Li; Walter Desmet; Mohamed Abdel-Wahab; Klaus Tiroch; Christian Hengstenberg; Isabell Bernlochner; Marcus Fischer; Heribert Schunkert; Karl-Ludwig Laugwitz; Albert Schömig; Julinda Mehilli; Adnan Kastrati
Journal:  Eur Heart J       Date:  2015-01-23       Impact factor: 29.983

10.  6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial.

Authors:  Sung-Jin Hong; Dong-Ho Shin; Jung-Sun Kim; Byeong-Keuk Kim; Young-Guk Ko; Donghoon Choi; Ae-Young Her; Yong Hoon Kim; Yangsoo Jang; Myeong-Ki Hong
Journal:  JACC Cardiovasc Interv       Date:  2016-05-17       Impact factor: 11.195
View more
  1 in total

Review 1.  Antiplatelet Therapy with Integrated Traditional Chinese and Western Medicine for Use in Myocardial Ischemia-Reperfusion Injury: A Review of Clinical Applications and Mechanisms.

Authors:  Yuxuan Li; Yan Li; Bin Li; Yang Liu; Jingqian Zhang; Wu Kuang; Jinjin Lu; Zheng Cao; Jie Cui; Zongjing Fan; Bin Guo; Dong Li
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-20       Impact factor: 2.629
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.